Regeneron Converts Interleukin-1 Antibody Opt-In Rights to Royalty Agreement

Thursday, June 11, 2009 1 min read

Key Takeaway: Regeneron Converts Interleukin-1 Antibody Opt-In Rights to Royalty Agreement